CN104094119A - 用于胞内传递生物活性分子的官能化纳米粒子 - Google Patents

用于胞内传递生物活性分子的官能化纳米粒子 Download PDF

Info

Publication number
CN104094119A
CN104094119A CN201280063870.2A CN201280063870A CN104094119A CN 104094119 A CN104094119 A CN 104094119A CN 201280063870 A CN201280063870 A CN 201280063870A CN 104094119 A CN104094119 A CN 104094119A
Authority
CN
China
Prior art keywords
cells
nanoparticles
cell
nanoparticle
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280063870.2A
Other languages
English (en)
Chinese (zh)
Inventor
安德拉尼克·安德鲁·阿普里克彦
基利恩·迪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEMGENICS Inc
Original Assignee
STEMGENICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEMGENICS Inc filed Critical STEMGENICS Inc
Priority to CN201610644097.9A priority Critical patent/CN106822868A/zh
Publication of CN104094119A publication Critical patent/CN104094119A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/34—Belt retractors, e.g. reels
    • B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
    • B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/289—Energy-absorption curves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
CN201280063870.2A 2011-10-21 2012-10-22 用于胞内传递生物活性分子的官能化纳米粒子 Pending CN104094119A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610644097.9A CN106822868A (zh) 2011-10-21 2012-10-22 用于胞内传递生物活性分子的官能化纳米粒子

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550213P 2011-10-21 2011-10-21
US61/550,213 2011-10-21
PCT/US2012/061391 WO2013059831A1 (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610644097.9A Division CN106822868A (zh) 2011-10-21 2012-10-22 用于胞内传递生物活性分子的官能化纳米粒子

Publications (1)

Publication Number Publication Date
CN104094119A true CN104094119A (zh) 2014-10-08

Family

ID=48141479

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280063870.2A Pending CN104094119A (zh) 2011-10-21 2012-10-22 用于胞内传递生物活性分子的官能化纳米粒子
CN201610644097.9A Pending CN106822868A (zh) 2011-10-21 2012-10-22 用于胞内传递生物活性分子的官能化纳米粒子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610644097.9A Pending CN106822868A (zh) 2011-10-21 2012-10-22 用于胞内传递生物活性分子的官能化纳米粒子

Country Status (14)

Country Link
US (1) US9675708B2 (enExample)
EP (2) EP3400956A1 (enExample)
JP (3) JP2014532628A (enExample)
KR (3) KR20190077124A (enExample)
CN (2) CN104094119A (enExample)
AU (3) AU2012325723A1 (enExample)
BR (1) BR112014009753B1 (enExample)
CA (2) CA2938661A1 (enExample)
HK (1) HK1201089A1 (enExample)
IN (1) IN2014DN03224A (enExample)
MX (3) MX367656B (enExample)
RU (2) RU2018135567A (enExample)
SG (2) SG10201601746TA (enExample)
WO (1) WO2013059831A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105440112A (zh) * 2015-12-07 2016-03-30 国家纳米科学中心 多肽-白蛋白偶联药物、其制备方法及应用
CN108287235A (zh) * 2018-02-07 2018-07-17 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用
CN109641007A (zh) * 2016-06-03 2019-04-16 斯特姆詹尼克斯公司 用功能化纳米颗粒将人类体细胞直接重编程为选定的(预定的)分化细胞

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104094119A (zh) * 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
US10100332B2 (en) 2013-08-23 2018-10-16 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
CN106414723A (zh) * 2014-02-10 2017-02-15 纳维基因股份有限公司 细胞调节纳米组合物及使用方法
WO2017210666A2 (en) * 2016-06-03 2017-12-07 Stemgenics, Inc. Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
WO2018071572A1 (en) * 2016-10-11 2018-04-19 Stemgenics, Inc. Nanoparticles functionalized with gene editing tools and related methods
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
JP2020504177A (ja) * 2017-01-04 2020-02-06 ナノティックス，エルエルシー 捕捉粒子をアセンブルするための方法
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US11701433B2 (en) 2017-06-05 2023-07-18 The Regents Of The University Of Michigan Complexes for delivery of antigenic peptides
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
US20200326325A1 (en) 2019-04-12 2020-10-15 Lisa Diamond Nanosensor chip with compound nanopores
CN112111042B (zh) * 2019-06-21 2024-04-05 康码（上海）生物科技有限公司 一种生物磁性微球及其制备方法和使用方法
CN110642876A (zh) * 2019-10-10 2020-01-03 南京市口腔医院 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品
CN112472685B (zh) * 2020-12-10 2023-03-24 哈尔滨工业大学 一种杂化中性粒细胞机器人的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042753A1 (en) * 2003-04-30 2005-02-24 The Regents Of The University Of Michigan Drug delivery compositions
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
CN101389314A (zh) * 2005-03-14 2009-03-18 得克萨斯大学体系董事会 生物活性fus1肽和纳米颗粒-多肽复合物
US20100298536A1 (en) * 2007-10-02 2010-11-25 Seoul National University Industry Foundation Complex of cell translocational peptide and magnetic nanoparticles and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014252A (pt) * 1999-09-14 2002-11-19 Biomedical Apherese Systeme Gm Nanopartìculas magnéticas tendo atividade bioquìmica, método para sua produção e seus usos
WO2005080598A1 (ja) * 2004-02-19 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 体細胞核初期化物質のスクリーニング方法
EP1957045A2 (en) * 2005-03-14 2008-08-20 Board of Regents, The University of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
US20110182805A1 (en) * 2005-06-17 2011-07-28 Desimone Joseph M Nanoparticle fabrication methods, systems, and materials
US20080166412A1 (en) 2007-01-02 2008-07-10 Kiminobu Sugaya Methods and materials for stimulating proliferation of stem cell
KR100925689B1 (ko) * 2007-07-25 2009-11-10 한국생명공학연구원 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질
WO2009035541A1 (en) 2007-09-10 2009-03-19 Merck & Co., Inc. Method of treating inherited severe neutropenia
AU2008329562A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Sox2 protein
CA2713872A1 (en) 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
DK2417262T3 (da) * 2009-04-07 2015-06-22 Dow Agrosciences Llc Nanopartikelmedieret tilførsel af sekvensspecifikke nukleaser
CN104094119A (zh) * 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042753A1 (en) * 2003-04-30 2005-02-24 The Regents Of The University Of Michigan Drug delivery compositions
CN101389314A (zh) * 2005-03-14 2009-03-18 得克萨斯大学体系董事会 生物活性fus1肽和纳米颗粒-多肽复合物
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
US20100298536A1 (en) * 2007-10-02 2010-11-25 Seoul National University Industry Foundation Complex of cell translocational peptide and magnetic nanoparticles and use thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105440112A (zh) * 2015-12-07 2016-03-30 国家纳米科学中心 多肽-白蛋白偶联药物、其制备方法及应用
CN109641007A (zh) * 2016-06-03 2019-04-16 斯特姆詹尼克斯公司 用功能化纳米颗粒将人类体细胞直接重编程为选定的(预定的)分化细胞
CN114634908A (zh) * 2016-06-03 2022-06-17 斯特姆詹尼克斯公司 用功能化纳米颗粒将人类体细胞直接重编程为选定的(预定的)分化细胞
CN108287235A (zh) * 2018-02-07 2018-07-17 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用
CN108287235B (zh) * 2018-02-07 2021-03-09 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用

Also Published As

Publication number Publication date
AU2018203848A1 (en) 2018-06-21
SG10201601746TA (en) 2016-04-28
RU2014120465A (ru) 2015-11-27
MX367656B (es) 2019-08-29
BR112014009753B1 (pt) 2020-09-15
WO2013059831A1 (en) 2013-04-25
JP2017165781A (ja) 2017-09-21
US20140342004A1 (en) 2014-11-20
EP2769217A4 (en) 2015-06-03
JP2018184485A (ja) 2018-11-22
IN2014DN03224A (enExample) 2015-05-22
US9675708B2 (en) 2017-06-13
SG11201401658SA (en) 2014-07-30
CN106822868A (zh) 2017-06-13
MX2018010696A (es) 2020-09-02
JP6560302B2 (ja) 2019-08-14
JP2014532628A (ja) 2014-12-08
KR20190077124A (ko) 2019-07-02
KR20150001711A (ko) 2015-01-06
CA2853128A1 (en) 2013-04-25
CA2853128C (en) 2016-09-27
AU2012325723A1 (en) 2014-05-15
HK1201089A1 (en) 2015-08-21
RU2018135567A (ru) 2018-11-15
MX2014004778A (es) 2014-10-17
AU2020223737A1 (en) 2020-09-17
KR20200040924A (ko) 2020-04-20
CA2938661A1 (en) 2013-04-25
EP2769217A1 (en) 2014-08-27
BR112014009753A2 (pt) 2017-04-25
EP3400956A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
CN104094119A (zh) 用于胞内传递生物活性分子的官能化纳米粒子
Chan et al. Intracellular protein delivery: approaches, challenges, and clinical applications
HK1225745A1 (zh) 自组装肽、肽模拟物和肽缀合物作为构件用於生物制造和打印
EP3463316A2 (en) Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
US20180223260A1 (en) Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use
Xu et al. Delivery of plasmid IGF‐1 to chondrocytes via cationized gelatin nanoparticles
Bharti et al. Nanotechnology in stem cell research and therapy
US20220127317A1 (en) Antitumor cell comprising a charge modified globin
HK1236412A1 (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
HK1236412A (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
US20060210530A1 (en) Polymer coating of cells
KR20190028665A (ko) 기능화된 나노입자(functionalized nanoparticles)를 사용하여 선택된(예정된) 분화된 세포에 대한 사람 체세포의 직접적인 재프로그래밍
US20230116019A1 (en) Nanoparticles for expression of genes of interest and/or regulation of signaling pathways
HK40078277A (en) Direct reprogramming of a human somatic cell to a selected (predetermined) differentiated cell with functionalized nanoparticles
US20200181647A1 (en) Biologically active synthetic nanoparticle constructs and methods of use thereof
Ma Engineered Biomaterials for Human Neural Stem Cell Applications
Patel NanoScript: A nanoparticle-based biomimetic platform for stem cell reprogramming

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201089

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141008

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201089

Country of ref document: HK